Clinical Trial Update: Pembrolizumab for Newly Diagnosed Glioblastoma [Phase 2]

View source ↗

Summary

An active Phase 2 clinical trial is evaluating pembrolizumab for newly diagnosed glioblastoma, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Zurich | Conditions: Newly Diagnosed Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING